Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront abiraterone versus docetaxel with ADT in high-risk metastatic hormone-naive prostate cancer
jRCTs021180021Completed
- Start
- Apr 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of abiraterone and docetaxel in prostate cancer (PCa) (3 arms). Primary endpoint: Metastatic free survival. Started Apr 2016; status: completed.
02
Drugs
abirateronedocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs021180021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180021.